We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Quantum Phar. | QP. | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 84.2374 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 84.2374 | 84.2374 |
| Top Posts |
|---|
Posted at 16/8/2017 18:52 by duncan doughnut Well I'm home tonight to see my CLIN are in talks to buy my QP. and both shares are up :-] That's a win/win for me.CLIN are trading on a much higher rating that QP. so they can pay a good price and it would still be earnings enhancing. CLIN are making their move now before the growth here really starts to show. I think the new board will hold out for a good price as they haven't even had time to stamp their mark and the company would be taken away from them just as they were going to get the credit. CLIN are 10 times the size of QP., easily in their scope to buy. Bid has to be in 3 fig share price I'd say, if it's to go through. Perhaps after the interims investors will get a better idea of the value here and appreciate what a bid price would need to be. |
Posted at 08/8/2017 12:40 by rivaldo New interview with the CEO:Extracts: "Quantum Pharma 'fundamentally successful' in simplifying strategy, says chief executive" "Quantum Pharma’s new business model has been hailed as a “fundamental success” by chief executive Chris Rigg, three months after he closed the company’s struggling NuPharm division." "Mr Rigg said that Quantum’s effort to focus its business is now paying off. Speaking to The Journal Mr Rigg said: “The position that the business brought to float was the ability to convert unlicensed medicines to licensed. It then acquired NuPharm. “It was the business I closed, and it was a business that was failing. It was acquired for the right strategic intent but it was failing. “Part of what I have done is to focus and simplify the business. “When you license a product we bring it to market at a lower price than the unlicensed medicine. We can do that as we get a higher market share and manufacture it in bulk. “The aim is to drive into the future the benefits of the license programme to lower prices in the NHS.” Under the renewed strategy Quantum is focusing on its core business. This is largely the supply of unlicensed medications – known as specials – and the creation of licensed products through its Colonis arm. With its network of pharmacies across the UK, Quantum is a market leader in supplying adapted medicines to the market. This process can involve making liquid versions of pills or changing the flavour of medication. One of the key areas for growth for the firm is Colonis and its licensing division. Once a drug successfully attains a UK license the business involves becomes the only one able to distribute the medication to pharmacies. This gives its a major market advantage. As part of the new model Mr Rigg has appointed new management teams to oversee its divisions, including Colonis. “From a control perspective it allows you to focus,” said Rigg. “You can change and make people accountable.” Despite writing off £13.7m as a result of the NuPharm sale, Mr Rigg said investors reacted well to the renewed focus on its core business. The company’s share price reflected his optimism, and following the closure of NuPharm, Quantum’s share price soared from 43p to 60p over seven days. The price has since levelled off and at the time of writing sits at 55.25p." |
Posted at 09/5/2017 13:36 by grosvenor11 Previous strategy based on creating broad based Pharma company with investment needed in new business units to achieve profitability. Only real issue was too much optimism in terms of new product launches given MHRA timelines.New strategy based on max sustainable profit & exit (driven by investors) You can certainly trust that they have an eye on maximising their return! |
Posted at 04/5/2017 14:19 by aishah Fool write-up:This emerging growth business looks too cheap Kevin Godbold | Wednesday, 3rd May, 2017 | Sometimes change, or something new within an existing organisation, can drive an improving outlook for a firm and accelerate returns for the company?s investors. A company under transition I reckon Quantum Pharma (LSE: QP) is poised to behave in the way I describe above as the firm transitions to a more focused and simplified business strategy led by a new board of directors. The company develops and manufactures niche pharmaceutical products for the retail, wholesale, hospital and home care markets, and full-year results out today show revenue up 28% compared to a year ago, suggesting that the firm continues to gain… |
Posted at 22/2/2017 18:34 by up protherics Investor RoadshowINMO I think the investor roadshow is a positive sign..Generally companies try to gauge from investors as to what drives them to invest in a stock.. They also try to see how in a positive way they can release RNS announcements without misleading investors together with how they time them. A roadshow like this is not the same as an IPO roadshow so hopefully we will see some positive buying on the back of it. |
Posted at 21/2/2017 17:12 by r ball I'm always wary of roadshows. Why bother if you don't want to raise money. It's managements job to run the business not pander to existing investors or the share price. |
Posted at 09/2/2017 19:57 by up protherics Most of the placing shares are held by one investor Harwood..From past experience they will want to hold the stock until they get a decent return.. Judging by the the price the options have been fixed at we should be looking at northwards of 1.40 within three years.. That's of course if everything goes well.As a separate issue does anyone know how much royalties quantum receive on MED2002..and are they involved with phase 111 trialing |
Posted at 05/10/2016 13:16 by rosejs2 Institutions currently appear to be supportiveMajor Shareholders As at 5 October 2016, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company: Shares Held % Legal & General Investment Management 15,701,800 12.56% Aviva Investors Global Services 8,910,561 7.12 Fidelity Worldwide Investments as agent for certain funds 8,870,000 7.10 AXA Investment Managers UK 8,650,000 6.92 River and Mercantile Asset Management 6,861,000 5.49 FIL Limited 6,642,676 5.31 Miton Asset Management 6,500,000 5.20 Sanne Fiduciary Services Limited 4,840,165 3.87 Slater Investments Ltd 4,063,468 3.25 Henderson Global Investors 4,000,000 3.20 Brian Kennedy 4,000,000 3.20 |
Posted at 14/9/2016 17:08 by cougar99 > patient investor ( if that exists anymore).Indeed, in this 'instant' world then there are fewer patient investors (traders) .... but that can be an advantage to investors that have a longer term outlook |
Posted at 14/6/2016 10:05 by ron manager See in the last RNS that QP are offering a site visit in late July. Extract from the statement below:Retail Investor Days Quantum Pharma is pleased to announce that it will be hosting two retail investor days in 2016. The first will be held at the Group's headquarters in Burnopfield, County Durham on Thursday, 28 July 2016 and will involve a presentation by Andrew Scaife (CEO) and Chris Rigg (CFO) followed by a tour of the facility and an opportunity to meet other members of the senior management team. The second investor day will be held in London at the offices of Buchanan, 107 Cheapside, London EC2V 6DN, on Wednesday, 30 November 2016 and this will involve a presentation by Andrew Scaife (CEO) and Chris Rigg (CFO) followed by a question and answer session. No new material information will be made available on either of the retail investor days and copies of the presentations will be made available via the Group's investor relations website on the day of each meeting. To register interest and receive further information on either proposed date, please email your details through to retailinvestors@buch DYOR Ron |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
